Combination of molecular-targeted drugs with endocrine therapy for hormone-resistant breast cancer.

about

Current medical treatment of estrogen receptor-positive breast cancer Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells.Molecular diagnostics for precision medicine in breast cancer treatment: what does the future hold?

P2860

Q26795751-E7ABAB46-8DAD-4118-AA7F-117F8350DA03 Q38818614-0F079D24-C5B8-455B-B26D-9309720C1193 Q48332966-4D95CF5A-0EA8-4668-AB37-6888AF6F1638

P2860

Combination of molecular-targeted drugs with endocrine therapy for hormone-resistant breast cancer.

Item

http://www.wikidata.org/entity/Q38364580

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Combination of molecular-targe ...... rmone-resistant breast cancer.

@en

type

Item

label

Combination of molecular-targe ...... rmone-resistant breast cancer.

@en

prefLabel

Combination of molecular-targe ...... rmone-resistant breast cancer.

@en

P1476

Combination of molecular-targe ...... rmone-resistant breast cancer.

@en

P2093

Reiko Kimura-Tsuchiya

http://www.w3.org/2001/XMLSchema#string

Shigehira Saji

http://www.w3.org/2001/XMLSchema#string

P2860

Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer

Brain metastases in breast cancer

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

Detecting an overall survival benefit that is derived from progression-free survival

Is breast cancer survival improving?

A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer

Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer.

Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal a

Evolving approaches to metastatic breast cancer patients pre-treated with anthracycline and taxane

Histone deacetylase inhibitor induced modulation of anti-estrogen therapy.

P2888

s10147-015-0799-2

P304

268-272

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10147-015-0799-2

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-02-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25708592

http://www.w3.org/2001/XMLSchema#string

Combination of molecular-targeted drugs with endocrine therapy for hormone-resistant breast cancer.

about

P2860

P2860

Combination of molecular-targeted drugs with endocrine therapy for hormone-resistant breast cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698